ArriVent Announces First Patient Dosed with ARR-002 ADC
ArriVent dosed its first patient in a Phase 1 trial for its dual-target ADC ARR-002, extending its portfolio of antibody-drug conjugates for ovarian and endometrial cancer.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed